IP Library Granted Patent US 8,551,498
Granted Patent B2
US 8,551,498 · App. 13/234,424 · Granted Oct 8, 2013

Solid composition containing

Inventor: Tiziano Prato (Varese, IT)
Assignee: Sanofi-Aventis S.p.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,551,498
App. No.
13/234,424
Granted
Oct 8, 2013
Kind
B2
Abstract

The invention relates to a composition of spores of nonpathogenic bacteria of the Bacillus genus, adsorbed onto a matrix made up of at least one water-insoluble adsorbent compound and a cellulose derivative, which can be obtained by the fluidized air bed technique, useful in the pharmaceutical, veterinary and nutrition fields.

Claims (16)

1. A composition comprising live spores of nonpathogenic bacteria of the Bacillus genus obtained by applying a liquid suspension of the live spores onto a matrix of a water-insoluble adsorbent compound and a cellulose derivative using a fluidized air bed technique.

2. The composition of claim 1 , wherein the cellulose derivative is microcrystalline cellulose.

3. The composition of claim 1 , wherein the adsorbent compound is selected from the group consisting of kaolin and calcium carbonate.

4. The composition of claim 1 , wherein the ratio by weight of the adsorbent compound to the cellulose derivative is between 90:10 and 10:90.

5. The composition of claim 4 , wherein the ratio is between 70:30 and 30:70.

6. The composition of claim 5 , wherein the ratio is approximately 50:50.

7. The composition of claim 1 , wherein the composition is in the form of a dosage unit in gel capsules or sachets.

8. The composition of claim 7 , wherein each dosage unit contains from 1 to 10 billion live spores, from 50 to 500 mg of kaolin, and from 50 to 600 mg of microcrystalline cellulose.

9. The composition of claim 8 , wherein each dosage unit contains from 2 to 5 billion live spores, from 50 to 250 mg of kaolin, and from 50 to 300 mg of microcrystalline cellulose.

10. The composition of claim 7 , wherein each dosage unit contains approximately 2 billion live spores in gel capsules.

11. The composition of claim 7 , wherein each dosage unit contains approximately 6 billion live spores in gel capsules.

12. The composition of claim 1 , wherein the live spores are live spores of Bacillus subtilis or Bacillus clausii.

13. The composition of claim 1 , wherein the live spores originate from one or more strains of Bacillus clausii that are deposited in the Collection Nationale De Cultures De Microorganisms of the Institut Pasteur under accession numbers I-273, I-274, I-275, and I-276.

14. The composition of claim 1 , wherein the composition contains from 3 to 30 billion live spores per gram of composition.

15. The composition of claim 14 , wherein the composition contains from 5 to 20 billion live spores per gram of composition.

16. The composition of claim 15 , wherein the composition contains approximately 10 billion live spores per gram of composition.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2013
From: PRATO, TIZIANO
To: SANOFI-SYNTHELABO OTC SPA
Reel/Frame 031167/0372 →
MERGER Recorded Sep 9, 2013
From: SANOFI-SYNTHELABO OTC SPA
To: SANOFI-AVENTIS SPA
Reel/Frame 031189/0947 →
Priority Claims (1)
IT MI2001A1632 · Jul 27, 2001 · national
Continuity (2)
Continuation 10484937
Related Publication 20120009167A1 · Jan 12, 2012